启迪药业(000590) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥77,093,552.53, a decrease of 23.82% compared to ¥101,199,883.45 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥8,284,339.28, representing a decline of 225.81% from a profit of ¥6,584,800.39 in Q1 2023[5] - The company's net loss for the period was RMB 44.00 million, compared to a loss of RMB 35.72 million at the beginning of the period[17] - The company reported a net loss of ¥8,266,488.58 for the current period, compared to a net profit of ¥6,608,510.61 in the previous period[20] - Basic and diluted earnings per share are both -¥0.0346, compared to ¥0.0275 in the previous period[20] Cash Flow and Liquidity - The net cash flow from operating activities improved by 40.82%, amounting to -¥42,259,969.07 compared to -¥71,412,078.80 in the previous year[5] - The company generated ¥93,107,680.11 in cash from sales of goods and services, an increase from ¥64,155,042.80 in the previous period[21] - Cash and cash equivalents at the end of the period amount to ¥156,475,757.71, down from ¥181,835,488.02 at the end of the previous period[22] - The company's cash and cash equivalents decreased to RMB 166.60 million from RMB 189.77 million[15] - Investment activities resulted in a net cash outflow of -¥3,218,482.90, compared to -¥236,187.28 in the previous period[22] Assets and Liabilities - The total assets at the end of Q1 2024 were ¥1,163,479,014.43, reflecting a 1.07% increase from ¥1,151,120,901.66 at the end of the previous year[5] - Total liabilities increased to RMB 443.19 million from RMB 422.92 million, representing a rise of approximately 4.8%[16] - The total equity attributable to shareholders decreased to RMB 715.43 million from RMB 723.72 million, a decline of about 1.0%[17] - The company reported a total current asset of RMB 554.43 million, slightly up from RMB 539.55 million[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,135[10] - The largest shareholder, Tsinghua Tongfang Co., Ltd., held 25.15% of the shares, with 60,216,947 shares frozen[11] Investment and Acquisitions - The company acquired 55% equity of Wuhan Ming Shi Pharmaceutical Co., Ltd. for a cash consideration of RMB 141.35 million[13] - The company experienced a significant decrease in investment income, down 74.05% to ¥89,950.70 due to reduced returns from structured deposits[8] Operating Costs and Revenue - Total operating revenue for the current period is ¥77,093,552.53, a decrease of 23.8% compared to ¥101,199,883.45 in the previous period[18] - Total operating costs for the current period are ¥85,671,039.65, down from ¥94,851,970.71, reflecting a reduction of 9.7%[18] Research and Development - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the report[14] Borrowings - The company's short-term borrowings increased to ¥24,737,920.00, attributed to new bank loans[8] - The company raised ¥24,737,920.00 in borrowings during the current period, compared to ¥20,000,000.00 in the previous period[22] Audit Status - The company has not undergone an audit for the first quarter report[24]